-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Benzinga·09/17/2026 12:17:11
Listen to the news
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.